| Drug Name: | Lanreotide (108736-35-2) |
|---|---|
| PubChem ID: | 71349 |
| SMILES: | CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N |
| InchiKey: | PUDHBTGHUJUUFI-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents |
| Molecular Weight (dalton) | : | 1096.34 |
| LogP | : | 0.8216 |
| Ring Count | : | 5 |
| Hydrogen Bond Acceptor Count | : | 14 |
| Hydrogen Bond Donor Count | : | 13 |
| Total Polar Surface Area | : | 355.08 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Codeine (76-57-3) | Analgesic Effect Decreased | Antagonistic | Reduction in O-demethylation can reduce the active metabolite of codeine, which could reduce the analgesic effect of the drug. | Selective effects of somatostatin analogs on human drug-metabolizing enzymes |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category